Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib randomized withdrawal and long-term extension in chronic spontaneous urticaria (Japan)
jRCT2031220499Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of remibrutinib in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Novartis. Primary endpoint: Time to first composite event during randomized withdrawal (Epoch 1). Started Dec 2022; status: active, not recruiting.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCT2031220499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220499.